3.48
-0.09(-2.52%)
Currency In USD
| Previous Close | 3.57 |
| Open | 3.56 |
| Day High | 3.56 |
| Day Low | 3.44 |
| 52-Week High | 175.98 |
| 52-Week Low | 3.42 |
| Volume | 55,902 |
| Average Volume | 909,122 |
| Market Cap | 396,118 |
| PE | -0.01 |
| EPS | -313.92 |
| Moving Average 50 Days | 6.44 |
| Moving Average 200 Days | 30.78 |
| Change | -0.09 |
If you invested $1000 in Nuwellis, Inc. (NUWE) 10 years ago, it would be worth $0 as of September 28, 2025 at a share price of $3.48. Whereas If you bought $1000 worth of Nuwellis, Inc. (NUWE) shares 5 years ago, it would be worth $0 as of September 28, 2025 at a share price of $3.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuwellis Receives New US Patent Reinforcing Vivian™ Pediatric Device Focused on Safer, More Precise Ultrafiltration
GlobeNewswire Inc.
Sep 18, 2025 1:00 PM GMT
EDEN PRAIRIE, Minn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., a fluid management company, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021 on September 16, 2025, based on Application
Nuwellis, Inc. Participates in a Virtual Investor “What This Means” Segment
GlobeNewswire Inc.
Sep 17, 2025 2:16 PM GMT
Watch the “What This Means” segment here MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it particip
Nuwellis’ Vivian Receives $3 Million NIH Grant to Accelerate Pediatric Platform and Strengthen Fluid-Management Portfolio
GlobeNewswire Inc.
Sep 09, 2025 1:00 PM GMT
Awarded grant supports dedicated pediatric continuous renal replacement therapy (CRRT) device in development for patients between 2.5 and 20 kg where therapeutic options are scarce Company working to advance Vivian™ towards an investigational device